All In Biotech

Drug Trial Radar · NCT07354477

Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation

An Exploratory, Pilot, Single-site Study to Evaluate the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

9

Actual

Start

Feb 20, 2026

Primary completion

Oct 1, 2026

Study completion Oct 1, 2026

Sponsor

Lead sponsor
Qlaris Bio, Inc.Industry
Sponsor type
Industry
First posted
Jan 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Pilot, single-site, prospective study of QLS-111 0.015 % in subjects with NPDR, OAG or NTG

Conditions

  • Non-proliferative Diabetic Retinopathy (NPDR)
  • Open-angle Glaucoma (OAG)
  • Normal Tension Glaucoma (NTG)

Interventions

  • QLS-111 Ophthalmic Solution (0.015%)Drug

    QLS-111 (0.015%) administered BID for 7 days OU.

  • QLS-111 Ophthalmic Solution (0.075%)Drug

    QLS-111 (0.075%) administered BID for 7 days OU. Follows the 7 days where QLS-111 (0.015%) is administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in blood flow to the posterior segment of the eye.Time frame: Days 1 through 22

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Stanford University, Dept. of Ophthalmology

    Palo Alto, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.